p21基因的克隆及其对肺癌细胞生长的抑制

用反转录ＰＣＲ从正常人胚胎肺细胞中获得了ｐ２１基因ｃＤＮＡ,将其插入真核表达载体ｐＭＳＣＶｎｅｏ,构建成重组质粒,ｐＭＳ２１,并将其转染至肺癌细胞株Ａ５４９。通过集落形成观察到ｐ２１对肺癌细胞具有明显的抑制作用,经ＲＮＡ狭缝杂交、Ｗｅｓｔｅｒｎ ｂｌｏｔ分析和免疫细胞化学实验证实这是ｐ２１表达的结果。荷瘤裸鼠实验也进一步证实了ｐ２１对肺癌细胞具有明显的抑制作用。为ｐ２１的深入研究提供了基础。     

p21基因的克隆及其对肺癌细胞生长的抑制

用反转录PCR从正常人胚胎肺细胞中获得了p21基因cDNA,将其插入真核表达载体pMSCVneo,构建成重组质粒pMS21,并将其转染至肺癌细胞株A549。通过集落形成观察到p21对肺癌细胞具有明显的抑制作用,经RNA狭缝杂交、Western印迹分析和免疫细胞化学实验证实这是p21表达的结果。荷瘤裸鼠实验也进一步证实了p21对肺癌细胞具有明显的抑制作用。     

外源p21~(WAF1)转染对人成纤维细胞凋亡的影响

构建了有义和反义ｐ２１ＷＡＦ１ 逆转录病毒表达载体, 分别经脂质体包裹后转染人胚肺二倍体成纤维细胞（２ＢＳ）。Ｓｏｕｔｈｅｒｎ 印迹杂交证实转染细胞中外源ｐ２１ ＷＡＦ１ｃＤＮＡ 已整合入基因组中。与空载体转染细胞相比, 有义转染细胞的ｐ２１ＷＡＦ１ ｍ ＲＮＡ 表达上升; 细胞增殖速度明显减慢; 对丁酸钠诱导凋亡的敏感性降低, 表现在细胞存活率升高, 核ＤＮＡ 梯状断裂片段出现的时间滞后, 断裂片段浓度下降, 流式细胞计检测的凋亡峰面积缩小。而反义转染细胞的ｐ２１ＷＡＦ１ ｍ ＲＮＡ表达下降; 细胞增殖速度较快; 对丁酸钠诱导凋亡的敏感性上升, 有关表现与有义转染细胞相反。说明２ＢＳ细胞内ｐ２１ＷＡＦ１ 的表达量与其被丁酸钠诱导凋亡的能力呈负相关。     

反义癌基因c－jun对大鼠血管平滑肌细胞增殖的影响

构建可表达原癌基因ｃ－ｊｕｎ正义和反义ＲＮＡ的真核细胞表达载体,将其导入体外培养的大鼠血管平滑肌细胞（ＶＳＭＣ）后,经Ｎｏｒｔｈｅｒｎ分析证实,两种插入方向的ｃｊｕｎ基因均在ＶＳＭＣ中大量表达;￣３Ｈ－ＴｄＲ参入实验表明,ｃ－ｊｕｎ反义ＲＮＡ对ＶＳＭＣ的增殖具有显著抑制作用．提示用反义核酸抑制ｃ－ｊｕｎ表达对治疗某些由于ＶＳＭＣ增殖所引起的心血管病可能具有一定意义．     

外源p21^WAF1转染对人成纤维细胞调亡的影响

构建了有义和反义ｐ２１＾ＷＡＦ１逆转录病毒表达载体,分别经脂质体包裹后转染人胚肺二倍体成纤维细胞（２ＢＳ）。Ｓｏｕｔｈｅｒｎ印迹杂交证实转染细胞中源ｐ２１＾ＷＡＦ１ｃＤＮＡ已整合入基因组中,与空载体转染细胞相比,有义转染细胞的ｐ２１＾ＷＡＦ１ｍＲＮＡ表达上升;细胞增殖速度明显减慢;对丁酸钠诱导调亡的敏感性降低,表现在细胞存在活率升高,核ＤＮＡ梯状断裂片段出现的时间滞后,断裂片段浓度下降,流式细胞计     

764－3对血管平滑肌细胞增殖的影响

为寻找新型有效的ＡⅡ拮抗剂,本实验应用细胞计数、￣３Ｈ－ＴｄＲ掺入、逆转录─聚合酶链反应及放射免疫实验方法,研究了中药单体７６４－３对卒中易感型自发性高血压大鼠（ＳＨＲｓｐ）及其对照（ＷＫＹ大鼠）主动脉平滑肌细胞（ＡｓＭＣ）增殖的影响及其作用机制。结果表明：７６４－３可显著抑制ＡＳＭＣ增殖,并有剂量依赖性。２０ｍｇ／Ｌ的７６４－３可极显著地抑制ＡＳＭＣ上ＡⅡ受体（ＡＴ＿１）的ｍＫＮＡ表达（ＳＨＲｓｐ下降７６．３％,ＷＫＹ大鼠下降６１．６％）,并可降低ＳＨＲｓｐＡＳＭＣ内ＡⅡ含量（下降２０％）。推测７６４－３对ＡＳＭＣ增殖的抑制作用可能部分地是由于降低了ＡＴ＿１受体的基固表达引起。比较其对两种大鼠ＡＳＭＣ的抑制效率,发现它对ＳＨＲｓｐ的ＡＳＭＣ的作用更强。     

维生素E和微量元素Se对人肝癌细胞生长、分化及其癌基因表达的影响

本工作观察了体外环境中不同水平的维生素Ｅ和微量元素Ｓｅ对人肝癌细胞株（ＳＭＭＣ－７７２１）生长、分化和其癌基因（Ｎ－ｒａｓ、ｃ－ｍｙｃ）表达水平的影响。实验结果表明：高水平维生素Ｅ（２．４、９．２、２４．０ｎｍｏｌ／Ｌ）和Ｓｅ（０．１５、０．３０、０．６０ｎｍｏｌ／Ｌ）对肝癌细胞的集落形成率具有明显的抑制作用;生化分析显示高水平维生素Ｅ和微量元素Ｓｅ均可明显抑制环境中脂质过氧化的水平,Ｓｅ对癌细胞甲胎蛋白的分泌有明显的抑制作用,而维生素Ｅ作用不明显。细胞原位杂交发现维生素Ｅ浓度为２．４和９．２ｎｍｏ１／Ｌ时对细胞癌基因Ｎ－ｒａｓ的表达具有明显抑制作用;Ｓｅ浓度为０．１５和０．３０ｎｍｏｌ／Ｌ时对癌基因ｃ－ｍｙｃ的表达明显抑制。实验还观察了维生素Ｅ和Ｓｅ之间的叠加效应,结果显示除对环境中脂质过氧化的抑制作用具有叠加效果外,对其他指标没有明显作用。     

蛋白质N端豆蔻酰化修饰的基因工程表达偶联加工系统

对酵母ＮＭＴ基因在大肠杆菌中表达进行较详细的研究,进而构建了复制子为ｐ１５Ａ并含卡那霉素抗性基因的相容性表达质粒ｐＫＺＭＴ,将其与表达质粒ｐＣＺｍＣα１共转化进大肠杆菌ＢＬ２１（ＤＥ３）Ｆ′,进行双质粒表达偶联加工修饰研究,其中ｐＣＺｍＣα１表达底物蛋白小鼠ｃＡＭＰ依赖的蛋白激酶催化亚基α（ＰＫＡ-ｍＣα）。ＳＤＳＰＡＧＥ及Ｗｅｓｔｅｒｎｂｌｏｔ分析表明,双质粒表达系统中,ＰＫＡ-ｍＣα都得到了稳定的高表达,尤其在２３℃低温诱导表达时,表达产物的可溶性部分明显增多;而酵母ＮＭＴ被控制在有利于活性功能的可溶性低水平表达。［^３Ｈ］ｍｙｒｉｓｔｉｃａｃｉｄ标记测定及放射自显影的结果显示,在大肠杆菌中表达的重组ＰＫＡ-ｍＣα被豆蔻酰化修饰。     

小麦黄花叶病毒RNA228kDa蛋白基因的表达及表达产物抗血清的制备

根据小麦黄花叶病毒（ Ｗ Ｙ Ｍ Ｖ） 核苷酸序列测定结果,将 Ｗ Ｙ Ｍ Ｖ Ｒ Ｎ Ａ２ 上的２８ ｋ Ｄａ 蛋白基因克隆到ｐ Ｅ Ｔ１１ａ 上,构建了原核表达载体ｐ Ｅ２８３９ 。 Ｓ Ｄ Ｓ Ｐ Ａ Ｇ Ｅ 分析表明,经 Ｉ Ｐ Ｔ Ｇ 诱导,２８ ｋ Ｄａ蛋白基因在大肠杆菌 Ｂ Ｌ２１（ Ｄ Ｅ３）ｐ Ｌｙｓ Ｓ 中得到高效表达。以含表达产物的凝胶为抗原,免疫家兔,首次制备了小麦黄花叶病毒 Ｒ Ｎ Ａ２ 蛋白特异性抗血清。     

维生素E和微量元素Se对人肝癌细胞生长,分化及其癌基因…

本工作观察了体外环境中不同水平的维生素Ｅ和微量元素Ｓｅ对人肝癌细胞株（ＳＭＭＣ－７７２１）生长,分经和其癌基因（Ｎ－ｒａｓ,ｃ－ｍｙｃ）表达水平的影响,实验结果表明：高水平维生素Ｅ（２．４、９．２、２４：０ｎｍｏｌ／Ｌ）和Ｓｅ（０．１５,０．３０,０．６０ｎｍｏｌ／Ｌ）对肝癌细胞的集落形成率具有明显的抑制作用;生化分析显示高水平维生素Ｅ微量元素Ｓｅ均可明显抑制环境中脂质过氧化的水平,Ｓｅ对癌细胞甲     

Transcriptional activation of the MUC2 gene by p53

MUC2 is one of the major components of mucins that provide a protective barrier between epithelial surfaces and the gut lumen. We investigated possible alterations of MUC2 gene expression by p53 and p21(Sdi1/Waf1/Cip1) in a human colon cancer cell line, DLD-1, establishing subclones in which a tetracycline-regulatable promoter controls exogenous p53 and p21 expression. MUC2 mRNA more significantly increased in response to p53 than to p21. Unexpectedly, MUC2 expression was also induced in human osteosarcoma cells, U-2OS and Saos-2, by exogenous p53. We next performed a reporter assay to test the direct regulation of MUC2 gene expression by p53. Deletion and mutagenesis of the MUC2 promoter region showed that it contains two sites for transactivation by p53. Furthermore, an electrophoretic mobility shift assay indicated that p53 binds to those elements. We analyzed MUC2 expression in other cell types possessing a functional p53 after exposure to various forms of stress. In MCF7 breast cancer and A427 lung cancer cells, MUC2 expression was increased along with the endogenous p53 level by actinomycin D, UVC, and x-ray, but not in RERF-LC-MS lung cancer cells carrying a mutated p53. These results suggest that p53 directly activates the MUC2 gene in many cell types.     

Multifaceted p21 in carcinogenesis,stemness of tumor and tumor therapy

Cancer cells possess metabolic properties that are different from those of benign cells. p21, encoded by CDKN1A gene, also named p21^Cip1/WAF1, was first identified as a cyclin-dependent kinase regulator that suppresses cell cycle G1/S phase and retinoblastoma protein phosphorylation. CDKN1A (p21) acts as the downstream target gene of TP53 (p53), and its expression is induced by wild-type p53 and it is not associated with mutant p53. p21 has been characterized as a vital regulator that involves multiple cell functions, including G1/S cell cycle progression, cell growth, DNA damage, and cell stemness. In 1994, p21 was found as a tumor suppressor in brain, lung and colon cancer by targeting p53 and was associated with tumorigenesis and metastasis. Notably, p21 plays a significant role in tumor development through p53-dependent and p53-independent pathways. In addition, expression of p21 is closely related to the resting state or terminal differentiation of cells. p21 is also associated with cancer stem cells and acts as a biomarker for such cells. In cancer therapy, given the importance of p21 in regulating the G1/S and G2 check points, it is not surprising that p21 is implicated in response to many cancer treatments and p21 promotes the effect of oncolytic virotherapy.     

Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas.

BACKGROUND: Human FHIT (fragile histidine triad) gene is highly conserved gene homologous to a group of genes identified in prokaryotes and eukaryotes. Loss of FHIT function may be important in the development and/or progression of various types of cancer. MATERIALS AND METHODS: We undertook a clinical study to analyze the relation between aberrant function of FHIT gene, tumor cell proliferation, and intensity of apoptosis as well as prognostic output in lung and squamous cell head and neck carcinoma (HNSCC). Status of FHIT gene, expression of p21waf1, intensity of apoptosis, and cell proliferation were analyzed in HNSCC and lung carcinoma tissues by molecular genetic methods, immunohistochemistry, [3H]-thymidine labeling method, and FACScan analysis in frozen and paraffin-embedded tissue sections. RESULTS: The majority of the malignant lung and HNSCC lesions displayed aberrant expression of FHIT gene, followed by low or negative expression of p21waf1, and increased intensity of cell proliferation. Similar results were obtained on synchronous combinations of normal, precancerous, and cancerous head and neck tissues. The observed changes increased with progression of these lesions. We examined tumor and corresponding normal tissue samples for microsatellite markers D3S1300 and D3S4103 to evaluate the loss of heterozygosity (LOH) at the FHIT gene loci. We found high percentage of LOH in both lung tumors and HNSCC (75% for D3S1300 and 79% for D3S4103 in lung cancer, and 87% for D3S1300 and 78% for D3S4103 in HNSCC). The median survival time of the patients suffering from lung cancer without FHIT protein expression was 22.46 months and that of the patients with FHIT expression 36.04 months. FHIT-negative cases tended to correlate with a worse prognosis, but this was not statistically significant. Median survival time of HNSCC patients without FHIT protein expression was 30.86 months and that of the patients with FHIT expression was 64.04 months (p < 0.05). CONCLUSIONS: Our results show a correlation between aberrant FHIT expression, a low rate of apoptosis, and high tumor cell proliferation. Aberrant FHIT gene could be a prognostic marker in lung cancer.     

miR-670-5p对肺癌细胞增殖、迁移、侵袭的影响

目的: 探讨miR-670-5p对肺癌细胞增殖、迁移和侵袭的影响,分析其调控WW结构域氧化还原酶基因(WWOX)的机制。方法: 收集2016年1月至2017年10月收治的28例肺癌组织和对应癌旁组织,实时荧光定量PCR(RT-qPCR)检测肺癌组织、癌旁组织中miR-670-5p的表达水平。将肺癌细胞A549分为anti-miR-NC组(转染anti-miR-NC)、anti-miR-670-5p组(转染anti-miR-670-5p)、anti-miR-670-5p+si-NC组(转染anti-miR-670-5p与si-NC)、anti-miR-670-5p+si-WWOX组(转染anti-miR-670-5p与si-WWOX)。转染48 h后,RT-qPCR或蛋白质印记(Western blot)检测转染效果。细胞计数试剂盒(CCK-8)检测细胞活力;Transwell实验检测细胞迁移和侵袭能力;Western blot检测P21、上皮细胞钙粘蛋白(E-cadherin)和基质金属蛋白酶2(MMP-2)蛋白的表达水平。双荧光素酶报告基因实验和Western blot验证miR-670-5p和WWOX的靶向关系。结果: 肺癌组织中miR-670-5p的表达水平较癌旁组织显著升高(P＜0.05)。抑制miR-670-5p可抑制MMP-2蛋白表达(P＜0.05),促进P21和E-cadherin表达(P＜0.05),抑制A549细胞增殖、迁移和侵袭(P＜0.05)。WWOX是miR-670-5p的靶基因,miR-670-5p负调控WWOX表达。抑制WWOX可部分逆转anti-miR-670-5p对A549细胞增殖、迁移和侵袭的影响(P＜0.05)。结论: miR-670-5p通过靶向WWOX能够促进肺癌细胞增殖、迁移、侵袭。     

稳定表达外源性p16基因肺癌A549细胞株的建立及鉴定

为构建稳定表达外源性抑癌基因p16的肺癌A549细胞株,用脂质体介导的基因转染方法,借助真核质粒表达载体（pcDNA3)。将抑癌基因p16转移入此基因缺失的人肺癌细胞株A549细胞中,经G418筛选,获得稳定表达的细胞克隆,用逆转录聚合酶链反应（RT-PCR）及免疫组织化学鉴定p16基因的表达,同时对克隆细胞分泌蛋白进行活性检测。结果显示转染p16基因的A549细胞中可以检测到p16mRNA及蛋白的表达,说明建立的p16真核表达载体能在肺肿瘤细胞中分泌表达蛋白,表达P16抑癌蛋白的A549细胞株的建立有助于研究抑癌基因p16在肺癌发生中的作用。     

MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1

We previously demonstrated that the epidermal growth factor receptor (EGFR) up-regulated miR-7 to promote tumor growth during lung cancer oncogenesis. Several lines of evidence have suggested that alterations in chromatin remodeling components contribute to cancer initiation and progression. In this study, we identified SMARCD1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily d, member 1) as a novel target gene of miR-7. miR-7 expression reduced SMARCD1 protein expression in lung cancer cell lines. We used luciferase reporters carrying wild type or mutated 3′UTR of SMARCD1 and found that miR-7 blocked SMARCD1 expression by binding to two seed regions in the 3′UTR of SMARCD1 and down-regulated SMARCD1 mRNA expression. Additionally, upon chemotherapy drug treatment, miR-7 down-regulated p53-dependent apoptosis-related gene BAX (BCL2-associated X protein) and p21 expression by interfering with the interaction between SMARCD1 and p53, thereby reducing caspase3 cleavage and the downstream apoptosis cascades. We found that although SMARCD1 sensitized lung cancer cells to chemotherapy drug-induced apoptosis, miR-7 enhanced the drug resistance potential of lung cancer cells against chemotherapy drugs. SMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell lines, and SMARCD1 and miR-7 expression levels were negatively correlated in clinical samples. Our investigation into the involvement of the EGFR-regulated microRNA pathway in the SWI/SNF chromatin remodeling complex suggests that EGFR-mediated miR-7 suppresses the coupling of the chromatin remodeling factor SMARCD1 with p53, resulting in increased chemo-resistance of lung cancer cells.     

MiR-517a-3p accelerates lung cancer cell proliferation and invasion through inhibiting FOXJ3 expression

Aims

Aberrant expression of microRNAs (miRNAs) results in alterations of various biological processes (e.g., cell cycle, cell differentiation, and apoptosis) and cell transformation. Altered miRNAs expression was associated with lung carcinogenesis and tumor progression. This study aimed to investigate the function and underlying molecular events of miR-517a-3p on regulation of lung cancer cell proliferation and invasion.

Main methods

Transfected miR-517a-3p mimics or inhibitors into 95D and 95C cells respectively, the effects of miR-517a-3p on lung cancer cell proliferation, migration, and invasion were detected. Bioinformatics software forecasted potential target genes of miR-517a-3p and dual luciferase reporter gene system and western blot verified whether miR-517a-3p regulates FOXJ3 expression directly.

Key findings

MiR-517a-3p was differentially expressed in lung cancer 95D and 95C cell lines that have different metastatic potential. Manipulation of miR-517a-3p expression changed lung cancer cell proliferation, migration and invasion capacity. MiR-517a-3p directly regulated FOXJ3 expression by binding to FOXJ3 promoter.

Significance

This study demonstrated that miR-517a-3p promoted lung cancer cell proliferation and invasion by targeting of FOXJ3 expression.